Prevalence of thromboembolic complications in patients with
atrial fibrillation in relation to a selected antithrombotic
therapy

J 2013

Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy

MÜLLER ZÁVALOVÁ, Veronika; Václav ŽIŽLAVSKÝ a Robert STAFFA

Základní údaje

Originální název

Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy

Autoři

MÜLLER ZÁVALOVÁ, Veronika; Václav ŽIŽLAVSKÝ a Robert STAFFA

Vydání

Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Palacký University, 2013, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.661

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/13:00071188

Organizační jednotka

Lékařská fakulta

UT WoS

000324728600006

Klíčová slova anglicky

atrial fibrillation; thromboembolism; anticoagulation; antiplatelet therapy

Příznaky

Recenzováno

Změněno: 13. 4. 2014 12:26, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Aim. The aim of this work was to find and characterize the correlation between the development of peripheral arterial thromboembolism and the selected medication for the atrial fibrillation-induced coagulopathy. Methods. The evaluated set included 103 patients admitted to the 2nd Department of Surgery, St. Anne’s University Hospital in Brno, during a period of 9 months. Patients were divided into individual groups on the basis of chronic medication of antithrombotic drugs, and the therapy effectiveness was evaluated on the basis of the thromboembolia prevalence. Results. In total, there were 36 thromboembolic complications; in 14 patients, it was a relapse. In the warfarin-administered group, thromboembolia occurred in 31.6 % patients and in the acetylsalicylic acid (ASA)-administered group, in 24.4 % of cases. The highest prevalence of peripheral arterial thromboembolism was observed in the group without any antithrombotic therapy, where this diagnosis was determined in 78.57 % of cases. A significant correlation (P=0.004; OR=7.94; CI 99% 1.183-53.33) was confirmed between the manifestation of coagulopathic states in patients with anticoagulation therapy and unmedicated patients. The smallest incidence of these complications was observed in the group with antiplatelet medication (P=0.0004; OR=11.33; CI 99% 1.693-75.89) compared to unmedicated patients. In the case of warfarin, the pharmacotherapy failure was caused by an insufficiently effective INR, which reached on average 1.42 +/- 0.53. Furthermore, a high impact of drug interactions cannot be definitely ruled out, especially in the case of antiplatelet ASA therapy, individually or in combination with clopidogrel.

Citovat

MÜLLER ZÁVALOVÁ, Veronika; Václav ŽIŽLAVSKÝ a Robert STAFFA. Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy. Biomedical Papers of the Faculty of Medicine of Palacký University. Olomouc: Palacký University, 2013, roč. 157, Suppl. 1, s. S71-S74, 4 s. ISSN 1213-8118.

@article{1160115,
   author = {Müller Závalová, Veronika and Žižlavský, Václav and Staffa, Robert},
   article_location = {Olomouc},
   article_number = {Suppl. 1},
   keywords = {atrial fibrillation; thromboembolism; anticoagulation; antiplatelet therapy},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers of the Faculty of Medicine of Palacký University},
   title = {Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy},
   url = {http://biomed.papers.upol.cz/incpdfs/pri-990000-0500_10_031.pdf},
   volume = {157},
   year = {2013}
}

TY  - JOUR
ID  - 1160115
AU  - Müller Závalová, Veronika - Žižlavský, Václav - Staffa, Robert
PY  - 2013
TI  - Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy
JF  - Biomedical Papers of the Faculty of Medicine of Palacký University
VL  - 157
IS  - Suppl. 1
SP  - S71-S74
EP  - S71-S74
PB  - Palacký University
SN  - 12138118
KW  - atrial fibrillation
KW  - thromboembolism
KW  - anticoagulation
KW  - antiplatelet therapy
UR  - http://biomed.papers.upol.cz/incpdfs/pri-990000-0500_10_031.pdf
N2  - Aim. The aim of this work was to find and characterize the correlation between the development of peripheral arterial thromboembolism and the selected medication for the atrial fibrillation-induced coagulopathy. Methods. The evaluated set included 103 patients admitted to the 2nd Department of Surgery, St. Anne’s University Hospital in Brno, during a period of 9 months. Patients were divided into individual groups on the basis of chronic medication of antithrombotic drugs, and the therapy effectiveness was evaluated on the basis of the thromboembolia prevalence. Results. In total, there were 36 thromboembolic complications; in 14 patients, it was a relapse. In the warfarin-administered group, thromboembolia occurred in 31.6 % patients and in the acetylsalicylic acid (ASA)-administered group, in 24.4 % of cases. The highest prevalence of peripheral arterial thromboembolism was observed in the group without any antithrombotic therapy, where this diagnosis was determined in 78.57 % of cases. A significant correlation (P=0.004; OR=7.94; CI 99% 1.183-53.33) was confirmed between the manifestation of coagulopathic states in patients with anticoagulation therapy and unmedicated patients. The smallest incidence of these complications was observed in the group with antiplatelet medication (P=0.0004; OR=11.33; CI 99% 1.693-75.89) compared to unmedicated patients. In the case of warfarin, the pharmacotherapy failure was caused by an insufficiently effective INR, which reached on average 1.42 +/- 0.53. Furthermore, a high impact of drug interactions cannot be definitely ruled out, especially in the case of antiplatelet ASA therapy, individually or in combination with clopidogrel.
ER  -

MÜLLER ZÁVALOVÁ, Veronika; Václav ŽIŽLAVSKÝ a Robert STAFFA. Prevalence of thromboembolic complications in patients with atrial fibrillation in relation to a selected antithrombotic therapy. \textit{Biomedical Papers of the Faculty of Medicine of Palacký University}. Olomouc: Palacký University, 2013, roč.~157, Suppl. 1, s.~S71-S74, 4 s. ISSN~1213-8118.

Přehled o publikaci